Novartis (NVS) Tops Q1 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as higher yields and oil prices flag inflation risk
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Oracle and these 6 stocks are newest addition to Mizuho Top Picks list
Sandoz (NVS) Receives Positive EMA CHMP Opinion on Pregabalin as Epilepsy and GAD Treatment
April 24, 2015 7:53 AM EDTOn 23 April 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Pregabalin Sandoz GmbH, intended for the treatment of epilepsy and generalized anxiety disorder. The applicant for this medicinal product is Sandoz GmbH, a unit of Novartis (NYSE:... More



